Analyst Ratings For Insys Therapeutics (NASDAQ:INSY)
Today, Insys Therapeutics (NASDAQ:INSY) stock was downgraded by Piper Jaffray Companies from Neutral to Underweight.
Some recent analyst ratings include
- 3/9/2018-Piper Jaffray Companies was Downgraded by analysts at Piper Jaffray Companies from a “Neutral ” rating to a ” Underweight” rating.
- 3/2/2018-Cann Reiterated Rating of Average.
- 11/12/2017-Oppenheimer Reiterated Rating of Hold.
Recent Insider Trading Activity For Insys Therapeutics (NASDAQ:INSY)
Insys Therapeutics (NASDAQ:INSY) has insider ownership of 67.90% and institutional ownership of 22.85%.
- On 8/11/2017 John N Kapoor Trust Dated Sept, Major Shareholder, bought 17,500 with an average share price of $8.93 per share and the total transaction amounting to $156,275.00.
- On 8/10/2017 Saeed Motahari, CEO, bought 5,500 with an average share price of $8.92 per share and the total transaction amounting to $49,060.00.
- On 6/14/2017 Saeed Motahari, CEO, bought 5,400 with an average share price of $11.10 per share and the total transaction amounting to $59,940.00.
- On 6/1/2017 Rohit Vishnoi, Director, bought 4,000 with an average share price of $14.14 per share and the total transaction amounting to $56,560.00.
- On 5/18/2017 Steven J Meyer, Director, bought 8,000 with an average share price of $12.21 per share and the total transaction amounting to $97,680.00.
- On 5/16/2017 Saeed Motahari, CEO, bought 4,500 with an average share price of $11.98 per share and the total transaction amounting to $53,910.00.
- On 11/4/2016 Steven J Meyer, Director, bought 10,000 with an average share price of $10.75 per share and the total transaction amounting to $107,500.00.
Recent Trading Activity for Insys Therapeutics (NASDAQ:INSY)
Shares of Insys Therapeutics closed the previous trading session at 7.08 down -0.59 7.73% with 555574 shares trading hands.